Latest Headlines

Latest Headlines

GlobeImmune's $69M IPO designed to build immunotherapy pipeline

GlobeImmune is hoping to ride the new wave of enthusiasm over immunotherapies to a successful IPO designed to raise up to $69 million.

Developing proteomic signatures focus pancreatic cancer therapy

Biodesix, a Boulder, CO-based company developing diagnostics based on mass spectrometry technology, has found a proteomic signature after its analysis of a clinical trial of GlobeImmune's GI-4000 cancer vaccine in pancreatic cancer.